Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Longeveron (LGVN)
NASDAQ:LGVN
Longeveron (LGVN) Stock Price & Analysis
306 Followers
LGVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.77 - $37.50
Previous Close$1.65
Volume595.88K
Average Volume (3M)8.80M
Market Cap
$15.84M
Enterprise Value$15.45M
Total Cash (Recent Filing)$2.29M
Total Debt (Recent Filing)$1.90M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 09, 2024EPS Estimate
-$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.62
Shares Outstanding6,348,624
10 Day Avg. Volume39,123,127
30 Day Avg. Volume8,800,026
Standard Deviation1.11
R-Squared0.00019
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)3.14
Price to Sales (P/S)169.88
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.09
Enterprise Value/Gross Profit69.89
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$12.00Price Target Upside593.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Longeveron News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressLomecel-B Phase 2b trial is progressing towards completion of enrollment, aiming to support future approval with its positive clinical results from earlier trials.
Financial StabilityLongeveron has enhanced its financial position, successfully raising capital to fund its operations well into the future, showcasing strong fiscal management.
Regulatory MilestonesAn upcoming FDA meeting to discuss Lomecel-B's development strategy could pave the way for regulatory approval, marking a significant step forward for patients with early Alzheimer's disease.
Bears Say
Analyst RecommendationLowering PT to $1.50 on Dilution from Recent Financings & Near-Term Capital Needs.
EarningsFinancial results report a net loss of $1.61 per share, wider than the forecasted net loss.
Stock PerformanceThe stock performed poorly on the data after an initial spike during premarket trading.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $0.77 and its highest was $37.50 in the past 12 months.
What is Longeveron’s market cap?
Currently, no data Available
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is Aug 09, 2024 which is in 34 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on May 14, 2024. The company reported -$1.61 earnings per share for the quarter, beating the consensus estimate of -$2.005 by $0.395.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -$1.17.
How many shares outstanding does Longeveron have?
Longeveron has 8,116,909 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$1.61 in its last earnings report, beating expectations of -$2.005. Following the earnings report the stock price went down -3.597%.
Which hedge fund is a major shareholder of Longeveron?
Among the largest hedge funds holding Longeveron’s share is Gamco Investors, Inc. ET AL. It holds Longeveron’s shares valued at N/A.
---
Longeveron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (593.64% Upside)
$12.00 (593.64% Upside)
Blogger Sentiment
Bullish
LGVN Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $700.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 74.5%
Last 30 Days ▲ 74.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.92%
12-Months-Change
Fundamentals
Return on Equity
-214.03%
Trailing 12-Months
Asset Growth
-55.74%
Trailing 12-Months
Company Description
Longeveron
Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
---
LGVN Stock 12 Month Forecast
Average Price Target
$12.00
▲(593.64% Upside)
Technical Analysis
Best Analysts Covering LGVN
1 Year
1 Year Success Rate
0/13 ratings generated profit
1 Year Average Return
-75.40%
reiterated a buy rating 4 months ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -75.40% per trade.
---